Skip to main content
logo
NextCell Pharma AB (STO:NXTCL)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.088
+0.008 (0.74%)
Sep 2, 2026, 5:08 PM CET

NextCell Pharma AB Financials Overview

Millions SEK. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Aug '25 Aug '24 Aug '23 Aug '22
Revenue
10.789.8311.0611.2813.966.23
Revenue Growth
5.27%-11.13%-1.90%-19.18%124.03%39.82%
Gross Profit
3.51.661.67-3.942.96-2.49
Operating Income
-42.57-39.46-35.89-43.17-41-35.02
Net Income
-42.11-38.79-35.14-41.96-39.81-34.55
Earnings Per Share
-0.33--0.46-1.03-1.16-1.01
EPS Growth
------

Revenue by Segment
Chart
Fiscal YearFY 2025
Period EndingAug '25
Stem Cell Banking
10.53
Other
0.4
Total
10.94

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Aug '25 Aug '24 Aug '23 Aug '22
Net Cash (Debt)
21.0926.0338.7246.7950.0397.12
Net Cash Growth
26.20%-32.77%-17.24%-6.47%-48.49%-30.22%
Net Cash Per Share
0.17-0.511.151.462.82
Cash & Investments
21.0926.0338.7246.7950.0397.12

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Aug '25 Aug '24 Aug '23 Aug '22
Operating Cash Flow
-44.68-41.76-38.86-37.78-43.83-33.31
Capital Expenditures
-1.63-4.81-4.18-0.08-4.1-7.59
Free Cash Flow
-46.31-46.57-43.05-37.86-47.92-40.9
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Aug '25 Aug '24 Aug '23 Aug '22
Gross Margin
32.48%16.84%15.07%-34.98%21.19%-40.03%
Operating Margin
-394.97%-401.24%-324.35%-382.79%-293.81%-562.26%
Pretax Margin
-390.69%-394.49%-317.62%-372.04%-285.28%-554.72%
Profit Margin
-390.69%-394.49%-317.62%-372.04%-285.28%-554.72%
FCF Margin
-429.66%-473.62%-389.04%-335.70%-343.41%-656.63%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Aug '25 Aug '24 Aug '23 Aug '22
PS Ratio
12.768.2811.788.238.8735.05